Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection.
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms
/ blood
Biomarkers, Tumor
Cell Line, Tumor
Cell Proliferation
Cholangiocarcinoma
/ blood
Combined Modality Therapy
Epithelial-Mesenchymal Transition
Female
Gene Knockdown Techniques
Humans
Male
Metalloendopeptidases
/ blood
Middle Aged
Neoplasm Grading
Neoplasm Staging
Prognosis
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
23
01
2018
revised:
21
07
2018
accepted:
19
10
2018
pubmed:
26
10
2018
medline:
28
2
2020
entrez:
25
10
2018
Statut:
ppublish
Résumé
Few studies have investigated prognostic biomarkers in patients with intrahepatic cholangiocarcinoma (ICC). Nardilysin (NRDC), a metalloendopeptidase of the M16 family, has been suggested to play important roles in inflammation and several cancer types. We herein examined the clinical significance and biological function of NRDC in ICC. High serum NRDC levels were associated with shorter overall survival and disease-free survival in the primary ( Serum NRDC, a possible surrogate marker reflecting the EMT state in primary tumors, predicts the outcome of ICC after surgical resection.
Identifiants
pubmed: 30352908
pii: 1078-0432.CCR-18-0124
doi: 10.1158/1078-0432.CCR-18-0124
doi:
Substances chimiques
Biomarkers, Tumor
0
Metalloendopeptidases
EC 3.4.24.-
nardilysin
EC 3.4.24.61
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
619-628Informations de copyright
©2018 American Association for Cancer Research.